● SUNY Upstate Medical University — Syracuse, New York

Kupalab researches acute myeloid leukemia cell states. How do they persist and change through treatment? What regulatory programs do different leukemias share? How do myelodysplastic neoplasms progress?

Our Research →Postdoc opportunity: express interest

● The central question

Two leukemias can share a genetic label and behave differently. Others carry different mutations, but rely on related cellular programs. Longitudinal samples and integrated measurements allow us to investigate this through gene expression, chromatin and cell-surface identity.

Follow the question →

● Open position

Postdoc
opportunity

We are looking for an exceptional postdoctoral researcher in AML genomics to help build Kupalab from the ground up. As our first postdoc, you will help establish the experimental foundations, shape the lab’s scientific direction and gain firsthand experience in building a research program.

Express interest →

● kupalab.ai

AI lab build.

From the ground up.

We are launching our lab just as AI is reinventing biology and medicine. This is an exciting time to be building lab infrastructure, including data pipelines and instrumentation. We are also exploring AI for interpreting multiomic data and recursive hypothesis generation. Navigate to kupalab.ai to read more about what we plan, how we build it and test it, and what actually works.

Follow the build journal ↗

Research programs

Beyond
the genotype.

01

A longitudinal map of AML cell states

Two patients with AML can carry the same genetic mutations yet have different disease courses. Through a longitudinal, multiomic study of AML, we aim to understand which molecular features are shared across genetic backgrounds, which change through treatment, and which remain essential to leukemic identity.

02

Shared KMT2A-Associated Regulatory Dependencies in AML

Different genetic forms of AML can rely on some of the same molecular pathways to survive. One example is the KMT2A–HOX/MEIS1 regulatory axis, which helps sustain leukemia across several AML subtypes. The development of menin inhibitors has shown how targeting a shared dependency can lead to effective therapies, although not all leukemias involving this pathway respond equally.

03

Myelodysplastic Neoplasms: From Population Health to Disease Progression

Our research in myelodysplastic neoplasms (MDS) examines the broader health burden of these diseases, differences in patient outcomes, and the biological changes underlying progression.

A lab project

AI
in the lab.

We are launching our lab just as AI is reinventing biology and medicine. This is an exciting time to be building lab infrastructure, including data pipelines and instrumentation. We are also exploring AI for interpreting multiomic data and recursive hypothesis generation. Navigate to kupalab.ai to read more about what we plan, how we build it and test it, and what actually works.

kupalab.ai ↗

From the journal